Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Merck Sharp & Dohme LLC | INDUSTRY |
| SERMAS | UNKNOWN |
| Molecular-Clinical Pharmacol/Instit.Translational Medicine/University Liverpool | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
This will be a cross-sectional population-based study carried out in the region of Madrid (6,468,322 inhabitants according to current census) to quantify the number of Co-meds in HIV-infected individuals on ART in the region of Madrid, categorized by age and gender, and to compare the number of Co-meds between the ART-treated population and HIV-uninfected population in the region of Madrid, categorized by age and gender.
This will be a cross-sectional population-based study carried out in the region of Madrid (6,468,322 inhabitants according to current census) to quantify the number of Co-meds in HIV-infected individuals on ART in the region of Madrid, categorized by age and gender, and to compare the number of Co-meds between the ART-treated population and HIV-uninfected population in the region of Madrid, categorized by age and gender.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| the number of Co-meds in HIV-infected individuals on ART | number of Co-meds in HIV-infected individuals on ART in the region of Madrid, categorized by age and gender. | 6 months |
| number of Co-meds between the ART-treated population and HIV-uninfected | the number of Co-meds between the ART-treated population and HIV-uninfected population in the region of Madrid, categorized by age and gender. | 6 months |
| prevalence of potential CSDIs between ARVs and Co-meds in ART-treated individuals | prevalence of potential CSDIs between ARVs and Co-meds in ART-treated individuals, with description of the types of harm expected from each different potential CSDIs identified | 6 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
ART-treated patients who picked up ARVs and of all HIV-uninfected individuals who picked up Co-meds in the study period.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Juan Berenguer, PhD | Contact | +34620038850 | jbb4@me.com |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided